Literature DB >> 21762883

Chronic neuropathic pain in mice reduces μ-opioid receptor-mediated G-protein activity in the thalamus.

Michelle R Hoot1, Laura J Sim-Selley, Dana E Selley, Krista L Scoggins, William L Dewey.   

Abstract

Neuropathic pain is a debilitating condition that is often difficult to treat using conventional pharmacological interventions and the exact mechanisms involved in the establishment and maintenance of this type of chronic pain have yet to be fully elucidated. The present studies examined the effect of chronic nerve injury on μ-opioid receptors and receptor-mediated G-protein activity within the supraspinal brain regions involved in pain processing of mice. Chronic constriction injury (CCI) reduced paw withdrawal latency, which was maximal at 10 days post-injury. [d-Ala2,(N-Me)Phe4,Gly5-OH] enkephalin (DAMGO)-stimulated [(35)S]GTPγS binding was then conducted at this time point in membranes prepared from the rostral ACC (rACC), thalamus and periaqueductal grey (PAG) of CCI and sham-operated mice. Results showed reduced DAMGO-stimulated [(35)S]GTPγS binding in the thalamus and PAG of CCI mice, with no change in the rACC. In thalamus, this reduction was due to decreased maximal stimulation by DAMGO, with no difference in EC(50) values. In PAG, however, DAMGO E(max) values did not significantly differ between groups, possibly due to the small magnitude of the main effect. [(3)H]Naloxone binding in membranes of the thalamus showed no significant differences in B(max) values between CCI and sham-operated mice, indicating that the difference in G-protein activation did not result from differences in μ-opioid receptor levels. These results suggest that CCI induced a region-specific adaptation of μ-opioid receptor-mediated G-protein activity, with apparent desensitization of the μ-opioid receptor in the thalamus and PAG and could have implications for treatment of neuropathic pain.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762883      PMCID: PMC3159154          DOI: 10.1016/j.brainres.2011.06.023

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  38 in total

1.  Chronic pain induces anxiety with concomitant changes in opioidergic function in the amygdala.

Authors:  Minoru Narita; Chihiro Kaneko; Kan Miyoshi; Yasuyuki Nagumo; Naoko Kuzumaki; Mayumi Nakajima; Kana Nanjo; Kiyomi Matsuzawa; Mitsuaki Yamazaki; Tsutomu Suzuki
Journal:  Neuropsychopharmacology       Date:  2006-04       Impact factor: 7.853

2.  Chronic constriction injury reduces cannabinoid receptor 1 activity in the rostral anterior cingulate cortex of mice.

Authors:  Michelle R Hoot; Laura J Sim-Selley; Justin L Poklis; Rehab A Abdullah; Krista L Scoggins; Dana E Selley; William L Dewey
Journal:  Brain Res       Date:  2010-04-07       Impact factor: 3.252

Review 3.  Alteration of intention and self-initiated action associated with bilateral anterior cingulotomy.

Authors:  R A Cohen; R F Kaplan; P Zuffante; D J Moser; M A Jenkins; S Salloway; H Wilkinson
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1999       Impact factor: 2.198

4.  Morphine, nortriptyline and their combination vs. placebo in patients with chronic lumbar root pain.

Authors:  Suzan Khoromi; Lihong Cui; Lisa Nackers; Mitchell B Max
Journal:  Pain       Date:  2006-12-19       Impact factor: 6.961

5.  Periaqueductal gray matter projections to midline and intralaminar thalamic nuclei of the rat.

Authors:  K E Krout; A D Loewy
Journal:  J Comp Neurol       Date:  2000-08-14       Impact factor: 3.215

6.  Differential brain opioid receptor availability in central and peripheral neuropathic pain.

Authors:  Joseph Maarrawi; Roland Peyron; Patrick Mertens; Nicolas Costes; Michel Magnin; Marc Sindou; Bernard Laurent; Luis Garcia-Larrea
Journal:  Pain       Date:  2006-11-29       Impact factor: 6.961

Review 7.  Recommendations for the pharmacological management of neuropathic pain: an overview and literature update.

Authors:  Robert H Dworkin; Alec B O'Connor; Joseph Audette; Ralf Baron; Geoffrey K Gourlay; Maija L Haanpää; Joel L Kent; Elliot J Krane; Alyssa A Lebel; Robert M Levy; Sean C Mackey; John Mayer; Christine Miaskowski; Srinivasa N Raja; Andrew S C Rice; Kenneth E Schmader; Brett Stacey; Steven Stanos; Rolf-Detlef Treede; Dennis C Turk; Gary A Walco; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

8.  Direct evidence for the involvement of endogenous beta-endorphin in the suppression of the morphine-induced rewarding effect under a neuropathic pain-like state.

Authors:  Keiichi Niikura; Minoru Narita; Michiko Narita; Atsushi Nakamura; Daiki Okutsu; Ayumi Ozeki; Kana Kurahashi; Yasuhisa Kobayashi; Masami Suzuki; Tsutomu Suzuki
Journal:  Neurosci Lett       Date:  2008-03-04       Impact factor: 3.046

9.  The absence of endogenous beta-endorphin selectively blocks phosphorylation and desensitization of mu opioid receptors following partial sciatic nerve ligation.

Authors:  M Petraschka; S Li; T L Gilbert; R E Westenbroek; M R Bruchas; S Schreiber; J Lowe; M J Low; J E Pintar; C Chavkin
Journal:  Neuroscience       Date:  2007-04-30       Impact factor: 3.590

10.  Morphine modulation of pain processing in medial and lateral pain pathways.

Authors:  Jin-Yan Wang; Jin Huang; Jing-Yu Chang; Donald J Woodward; Fei Luo
Journal:  Mol Pain       Date:  2009-10-13       Impact factor: 3.395

View more
  10 in total

Review 1.  Neuroplasticity of ascending and descending pathways after somatosensory system injury: reviewing knowledge to identify neuropathic pain therapeutic targets.

Authors:  P Boadas-Vaello; S Castany; J Homs; B Álvarez-Pérez; M Deulofeu; E Verdú
Journal:  Spinal Cord       Date:  2016-01-12       Impact factor: 2.772

Review 2.  Mechanism of opioid addiction and its intervention therapy: Focusing on the reward circuitry and mu-opioid receptor.

Authors:  Jia-Jia Zhang; Chang-Geng Song; Ji-Min Dai; Ling Li; Xiang-Min Yang; Zhi-Nan Chen
Journal:  MedComm (2020)       Date:  2022-06-22

3.  Gi protein functions in thalamic neurons to decrease orofacial nociceptive response.

Authors:  Jennifer Strand; Crystal Stinson; Larry L Bellinger; Yuan Peng; Phillip R Kramer
Journal:  Brain Res       Date:  2018-05-12       Impact factor: 3.252

4.  IL-4 deficiency is associated with mechanical hypersensitivity in mice.

Authors:  Nurcan Üçeyler; Tengü Topuzoğlu; Peter Schiesser; Saskia Hahnenkamp; Claudia Sommer
Journal:  PLoS One       Date:  2011-12-02       Impact factor: 3.240

5.  Pentoxifylline decreases allodynia and hyperalgesia in a rat model of neuropathic pain.

Authors:  A Vakili; Mj Shirvanian; Ha Safakhah; A Rashidy-Pour
Journal:  Daru       Date:  2011       Impact factor: 3.117

Review 6.  Opioids Resistance in Chronic Pain Management.

Authors:  Luigi A Morrone; Damiana Scuteri; Laura Rombolà; Hirokazu Mizoguchi; Giacinto Bagetta
Journal:  Curr Neuropharmacol       Date:  2017-04       Impact factor: 7.363

7.  Neurodynamics: is tension contentious?

Authors:  Richard Ellis; Giacomo Carta; Ricardo J Andrade; Michel W Coppieters
Journal:  J Man Manip Ther       Date:  2021-11-16

Review 8.  Monoaminergic and Opioidergic Modulation of Brainstem Circuits: New Insights Into the Clinical Challenges of Pain Treatment?

Authors:  Isaura Tavares; José Tiago Costa-Pereira; Isabel Martins
Journal:  Front Pain Res (Lausanne)       Date:  2021-07-05

Review 9.  Neural Plasticity in the Brain during Neuropathic Pain.

Authors:  Myeong Seong Bak; Haney Park; Sun Kwang Kim
Journal:  Biomedicines       Date:  2021-05-31

10.  The neural mobilization technique modulates the expression of endogenous opioids in the periaqueductal gray and improves muscle strength and mobility in rats with neuropathic pain.

Authors:  Fabio Martinez Santos; Leandro Henrique Grecco; Marcelo Gomes Pereira; Mara Evany Oliveira; Priscila Abreu Rocha; Joyce Teixeira Silva; Daniel Oliveira Martins; Elen Haruka Miyabara; Marucia Chacur
Journal:  Behav Brain Funct       Date:  2014-05-13       Impact factor: 3.759

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.